Literature DB >> 7497845

Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine.

N M Davies1.   

Abstract

PURPOSE: Adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDS) on the upper gastrointestinal (GI) tract and small intestine are well described. Evidence is also accumulating that implicate NSAIDS in inducing and exacerbating damage in the distal GI tract. The purpose of this review is to identify possible adverse effects of NSAIDS on the large intestine and increase the clinical awareness of these toxicologic effects.
METHODS: A literature review identified the diversity of toxicologic effects induced by NSAIDS in the large intestine. The epidemiology, pathogenesis, and clinical implications of these adverse effects are described.
RESULTS: NSAID use has been associated with colonic bleeding, iron deficiency anemia, strictures, ulcerations, perforations, diarrhea, and death. In addition, NSAIDS can exacerbate inflammatory bowel disease and ulcerative colitis. The prevalence of NSAID-induced large intestinal damage is unknown. Diagnosis can be made by colonoscopy and barium scans. Although the clinical presentation of NSAID-induced gastropathy and enteropathy, bleeding or perforation, may be more dramatic than colonopathy, the overall clinical significance of these adverse effects of NSAIDS on the large intestine has not been fully characterized.
CONCLUSIONS: This review illustrates that NSAID-induced large bowel toxicity can cause significant morbidity in some patients, ranging from profuse diarrhea, chronic blood loss, and iron deficiency anemia to fatality. The pathogenesis is likely multifactorial and is thought to be related to inhibition of prostaglandin synthesis. Because NSAIDS are widely prescribed and some are available without a prescription, heightened awareness of these toxicologic manifestations throughout the GI tract may reduce morbidity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497845     DOI: 10.1007/bf02049158

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  35 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Do calcium channel blockers and antimuscarinics protect against perforated colonic diverticular disease? A case control study.

Authors:  C R Morris; I M Harvey; W S L Stebbings; C T M Speakman; H J Kennedy; A R Hart
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Epidemiology of perforated colonic diverticular disease.

Authors:  C R Morris; I M Harvey; W S L Stebbings; C T M Speakman; H J Kennedy; A R Hart
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

4.  Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases.

Authors:  Corrado Rosario Asteria; Giacomo Batignani; Alessandro Garcea; Francesco Tonelli
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

5.  [NSAID-colonopathy].

Authors:  M Vieth
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

6.  Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs.

Authors:  Angela M Meyer; Nizar N Ramzan; Russell I Heigh; Jonathan A Leighton
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 7.  A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.

Authors:  Asheebo Rojas; Thota Ganesh; Wenyi Wang; Jennifer Wang; Raymond Dingledine
Journal:  Neurobiol Dis       Date:  2019-02-25       Impact factor: 5.996

Review 8.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

9.  Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.

Authors:  D C Devor; B D Schultz
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

Review 10.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.